Lonza Group AG (LZAGF)
Lonza Group AG (LZAGF) Stock Price, Analysis & Data
| Bid | 673.33 |
| Market Cap | 48.42B |
| Revenue (ttm) | 6.87B |
| Net Income (ttm) | 1.08B |
| Beta | 0.84 |
| EPS (ttm) | 19.06 |
| PE Ratio (ttm) | 36.37 |
| Forward PE | n/a |
| P/B (ttm) | 4.82 |
| P/S (ttm) | 7.05 |
| Earnings Date | Jan 28, 2027 |
| Ask | 711 |
| Volume | 45 |
| Avg. Volume (20D) | 365 |
| Open | 693.20 |
| Previous Close | 705.50 |
| Day's Range | 693.20 - 693.20 |
| 52-Week Range | 565.14 - 755.96 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $6.38 (0.92%) |
| Ex-Dividend Date | May 12, 2026 |
About LZAGF
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug subs...
Financial Performance
In 2025, Lonza's revenue was 6.53B, an increase of 19.18% compared to the previous year's 5.48B. Earnings were -275M, a decrease of -143.24%.
Financial StatementsAnalysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings?Wondering whether Lonza Group at about CHF 508 per share still makes sense for your portfolio, or if better value is available elsewhere? The stock has been fairly volatile recently, with a 4.8% decli...